We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
Read MoreHide Full Article
CareDx (CDNA - Free Report) shares ended the last trading session 13% higher at $61.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.6% gain over the past four weeks.
CareDx scored a strong price increase, driven by investor’s optimism after financial services firm, BTIG raised its price target to $74 from $60, while maintaining a Buy rating. In the second quarter of 2026, the company’s revenue increased 52% year over year, supported by a 61% growth in Testing services revenues.
This molecular diagnostics company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $122.35 million, up 22.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For CareDx, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CDNA going forward to see if this recent jump can turn into more strength down the road.
CareDx is part of the Zacks Medical Services industry. Charles River Laboratories (CRL - Free Report) , another stock in the same industry, closed the last trading session 6.2% higher at $294.44. CRL has returned -6% in the past month.
Charles River's consensus EPS estimate for the upcoming report has changed -0.2% over the past month to $2.96. Compared to the company's year-ago EPS, this represents a change of +21.8%. Charles River currently boasts a Zacks Rank of #2 (Buy).
View the Zacks #1 Rank List
Image: Bigstock
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA - Free Report) shares ended the last trading session 13% higher at $61.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.6% gain over the past four weeks.
CareDx scored a strong price increase, driven by investor’s optimism after financial services firm, BTIG raised its price target to $74 from $60, while maintaining a Buy rating. In the second quarter of 2026, the company’s revenue increased 52% year over year, supported by a 61% growth in Testing services revenues.
This molecular diagnostics company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $122.35 million, up 22.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For CareDx, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CDNA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
CareDx is part of the Zacks Medical Services industry. Charles River Laboratories (CRL - Free Report) , another stock in the same industry, closed the last trading session 6.2% higher at $294.44. CRL has returned -6% in the past month.
Charles River's consensus EPS estimate for the upcoming report has changed -0.2% over the past month to $2.96. Compared to the company's year-ago EPS, this represents a change of +21.8%. Charles River currently boasts a Zacks Rank of #2 (Buy).